Article

Asynchronous antigen expression in B lineage acute lymphoblastic leukemia.

Johns Hopkins Oncology Center, Pediatric Oncology, Baltimore, MD 21205.
Blood (Impact Factor: 9.78). 08/1988; 72(1):299-307.
Source: PubMed

ABSTRACT Cell surface phenotypes of 113 B lineage acute lymphocytic leukemia (ALL) cases, defined by the presence of HLA-DR and at least one B-cell-specific antigen (either CD19, CD20, or CD22), were compared with antigen-defined stages of normal B lymphocyte development. The cases were first evaluated for expression of HLA-DR, CD19, CD34, CD10, CD20, and CD22 by indirect one-color immunofluorescence. Pairwise comparisons of cell surface marker expression were performed for each leukemic sample: no correlations were observed for paired antigen expression on the leukemic samples using antigens expressed either early or late during normal B lymphoid development. Complete immunophenotypes of the cases were then compared with normal B-cell developmental stages. Sixteen different complete immunophenotypes were observed on the leukemias that were not found in normal marrow; at least 78% of the cases demonstrated such "asynchronous" combinations of B lymphoid-associated differentiation antigens. Several samples were subsequently studied by two-color immunofluorescence, and the presence of doubly labeled cells with "asynchronous" antigen combinations was confirmed. These results indicate that the majority of B lineage leukemias exhibit "developmental asynchrony," as compared with normal marrow B cells. The data further suggest that ALL cases do not accurately represent cells arrested at the stage where the leukemogenic event occurred. Rather, ALL appears to be a disease in which there may be maturation of leukemic blasts; but this maturation is "asynchronous" when compared with the normal developmental process.

Full-text

Available from: Judith E Karp, Nov 23, 2014
0 Followers
 · 
77 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The clinical utility of early response measures Approximately 80% of children with acute lymphoblastic leukemia (ALL) are cured with contemporary risk-directed treatment, with therapies of different intensities administered to patient groups with differential risks of relapse. Many different clinical and biological features are used to identify different risk groups. Early response to therapy, defined as the initial degree and rate of disease regression prior to end induction, is one of the most powerful. Simple enumeration of blasts remaining in peripheral blood (PB) or bone marrow (BM) at defined times during induction therapy is highly predictive of treatment outcome among large groups of patients with ALL.(1) The Berlin-Frankfurt-Munster (BFM) group showed in ALL-BFM 83 that the number of blasts remaining in the peripheral blood following seven days treatment with prednisone and a single dose of intrathecal methotrexate separates patients into two subgroups with divergent outcomes.(2) Prednisone good responders (PGR) consist of the approximately 90% of patients that have < 1000 blasts/ml remaining in the PB and have an excellent outcome. In contrast, prednisone poor responders (PPR) that have = 1000 blasts/
  • [Show abstract] [Hide abstract]
    ABSTRACT: CD22 is a cell surface glycoprotein restricted to normal and malignant B-cells and is the target of several anti-CD22 antibody-based cancer therapies. For therapeutic antibody-payload conjugates, it is important to understand the subcellular trafficking of anti-CD22 antibodies to optimize antibody and/or linker-drug properties to maximize anti-tumor efficacy. It is agreed that anti-CD22 antibodies rapidly internalize, but controversial whether they recycle or are degraded in lysosomes, and it is unclear if trafficking is antibody or cell-type dependent. No studies examined anti-CD22 trafficking to either pathway in B-cells over time by dual immunofluorescence microscopy, likely partly because multiple samples of suspension cells are tedious to stain. We overcame this by using DropArray(TM) , a novel wall-less 96-well plate technology allowing rapid simultaneous staining of suspension or adherent cells in small (10-20μl) volumes. We examined the time-course of trafficking of five different anti-CD22 antibodies in eight B-cell lines representing four B-cell cancer types and show that in all cases antibodies internalize within 5 minutes and recycle, with only small amounts eventually trafficking to lysosomes. CD22 also localizes to recycling endosomes at steady state in the absence of antibody. Our data may help explain the differential efficacies of anti-CD22 antibodies conjugated to different therapeutic payloads.
    Traffic 12/2013; DOI:10.1111/tra.12144 · 4.71 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: CD19 is ubiquitously expressed on CLL cells and is therefore an attractive candidate for antibody targeting. XmAb(®)5574 (aka MOR00208) is a novel humanized CD19 monoclonal antibody with an engineered Fc region to enhance Fc gamma receptor binding affinity. Here we report results of a first in human Phase I trial of XmAb5574 in patients with relapsed or refractory CLL. 27 patients were enrolled to 6 escalating dose levels, with expansion at the highest dose level of 12 mg/kg. 9 doses of XmAb5574 were infused over 8 weeks. No maximal tolerated dose was reached, and the drug was generally well tolerated, with infusion reactions of grades 1 and 2 being the most common toxicities. Grade 3 and 4 toxicities occurred in 5 patients and included neutropenia, thrombocytopenia, increased aspartate aminotransferase, febrile neutropenia, and tumor lysis syndrome. XmAb5574 showed preliminary efficacy, with 18 patients (66.7%) responding by physical exam criteria and laboratory studies, and 8 patients (29.6%) responding by CT criteria. Pharmacokinetics showed a half-life of 14 days with clearance that was not dose-dependent. In conclusion, this Phase I trial demonstrates safety and preliminary efficacy of a novel Fc engineered CD19 monoclonal antibody XmAb5574 and justifies movement into the Phase II setting. Trial is registered on clinicaltrials.gov: NCT01161511.
    Blood 10/2014; 124(24). DOI:10.1182/blood-2014-08-593269 · 9.78 Impact Factor